Stéphanie Badiou

Stéphanie Badiou

Auto-generated profile, based on publicly available information

Stéphanie Badiou

Laboratoire de Biochimie et Hormonologie, CHU Montpellier, Univ Montpellier 1, Montpellier, F-34295, cédex 5, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
SHSophie Huby
Sophie Huby
PGPhilippe Gelisse
Philippe Gelisse
JTJean-Jacques Tudesq
Jean-Jacques Tudesq
PLPierre Labauge
Pierre Labauge
CDClaire Duflos
Claire Duflos
GTGuillaume Taieb
Guillaume Taieb
Background and Objectives Chimeric antigen receptor (CAR) T-cell therapies have dramatically improved the prognosis of patients with relapsed or refractory hematologic malignancies; however, cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome (ICANS) occur in ∼100 and 50% of patients, respectively. This study aimed to determine whether EEG patterns may be considered as diagnostic tools for ICANS. Methods Patients who received CAR T-cell therapy at Montpellier University Hospital between September 2020 and July 2021 were prospectively enrolled. Neurologic signs/symptoms and laboratory parameters were monitored daily for 14 days after CAR T-cell infusion. EEG and brain MRI were performed between day 6 and 8 after CAR T-cell infusion. EEG was performed again on the day of ICANS occurrence, if outside this time window. All collected data were compared between patients with and without ICANS. Results Thirty-eight consecutive patients were enrolled (14 women; median age: 65 years, interquartile range: [55–74]). ICANS was observed in 17 of 38 patients (44%) after a median time of 6 days after CAR T-cell infusion (4–8). The median ICANS grade was 2 (1–3). Higher C-reactive protein peak (146 mg/L [86–256], p = 0.004) at day 4 (3–6), lower natremia (131 mmol/L [129–132], p = 0.005) at day 5 (3–6), and frontal intermittent rhythmic delta activity (FIRDA, p < 0.001) on EEG between days 6 and 8 after infusion were correlated with ICANS occurrence. FIRDA was only observed in patients with ICANS (N = 15/17, sensitivity of 88%) and disappeared after ICANS resolution, usually after steroid therapy. Except for hyponatremia, no other toxic/metabolic marker was associated with FIRDA (p = 0.002). The plasma concentration of copeptin, a surrogate marker of antidiuretic hormone secretion, assessed at day 7 after infusion, was significantly higher in patients with (N = 8) than without (N = 6) ICANS (p = 0.043). Discussion FIRDA is a reliable diagnostic tool for ICANS, with a sensitivity of 88% and a negative predictive value of 100%. Moreover, as this EEG pattern disappeared concomitantly with ICANS resolution, FIRDA could be used to monitor neurotoxicity. Finally, our study suggests a pathogenic pathway that starts with increased C-reactive protein, followed by hyponatremia and eventually ICANS and FIRDA. More studies are required to confirm our results. Classification of Evidence This study provides Class III evidence that FIRDA on spot EEG accurately distinguishes patients with ICANS compared with those without after CAR T-cell therapy for hematologic malignancy.

10 August 2022 in Clinica Chimica Acta
Verified
Journal Article
Closed access
SBStéphanie Badiou
Stéphanie Badiou
ADAnne-Marie Dupuy
Anne-Marie Dupuy
SCSéverine Cunat
Séverine Cunat
ADAgnès Delay
Agnès Delay
SAStéphanie Alcaraz
Stéphanie Alcaraz
FGFlorence Galtier
Florence Galtier

1 July 2016 in Annales de biologie clinique
Verified
Journal Article
Closed access
ABAnne-Sophie Bargnoux
Anne-Sophie Bargnoux
NKNils Kuster
Nils Kuster
MMMarion Morena-Carrere
Marion Morena-Carrere
GBGregory Baptista
Gregory Baptista
LCLeila Chenine
Leila Chenine
JCJean-Paul Cristol
Jean-Paul Cristol
New highly sensitive (hs) assays have challenged the interpretation of cardiac troponins (cTn) as markers of injury while natriuretic peptides remain the markers of choice for myocardial dysfunction. However, variability extracardiac factors such as age, gender and renal function may alter circulating levels. In chronic kidney disease (CKD), the increase in circulating levels of these biomarkers in the absence of cardiac disease underlines the problem of discriminative value for diagnosis as well as the need to redefine the thresholds. In addition, these biomarkers are of potential interest to stratify cardiovascular risk, the leading cause of death in CKD. The aim of this work is to clarify the effect of age and renal function on circulating levels of high-sensitivity troponins and natriuretic peptides.

22 November 2021 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
ADanne marie dupuy
anne marie dupuy
LRLuna Ruffel
Luna Ruffel
ABAnne Sophie Bargnoux
Anne Sophie Bargnoux
SBStéphanie Badiou
Stéphanie Badiou
JCJean Paul Cristol
Jean Paul Cristol
Article Analytical evaluation of the performances of a new procalcitonin immunoassay was published on November 22, 2021 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).

1 August 2021 in Clinica Chimica Acta
Verified
Journal Article
Open access
ADanne marie dupuy
anne marie dupuy
SBStéphanie Badiou
Stéphanie Badiou
VMValentin Montagnon
Valentin Montagnon
OBOlivier Beaufils
Olivier Beaufils
MSMustapha Sebbane
Mustapha Sebbane
JCJean Paul Cristol
Jean Paul Cristol
Recently, Ortho Clinical Diagnostics have launched a high sensitivity cardiac troponin I assay adapted on Vitros3600 / 5600. We aimed at evaluating the analytical and clinical performances using the 0/3-hour algorithm, of the Ortho hs-cTnI assay on the Vitros 3600® (Ortho Clinical Diagnostics, Illkirch, France) analyzer with comparison to Roche hs-cTnT assay on the Cobas8000/e801® module (Roche diagnostics, Meylan, France) and the Abbott STAT hs-cTnI assay on the Alinity i® (Abbott, Rungis, France) analyzer. Imprecision studies, linearity, limit of detection, and the interference to hemolysis were performed for Ortho hs-cTnI assay. The concordance study was based on results of troponin obtained from 160 patients with chest pain to the emergency department. Testing was performed simultaneously measuring the Roche hs-cTnT and the Ortho hs-cTnI, then on remaining sample the concentration of Abbott hs-cTnI (n = 150). We applied the 0/3h algorithm to rule out/rule in, in acute myocardial infarction. Analytical performances were acceptable and in accordance with manufacturer's data. For late presenters 100, 92.8 and 88.8% patients could be rule-out with Roche, Ortho and Abbott assay, respectively with one NSTEMI missed with both hs-TnI assays. Applying the hs-cTn cut-offs from 0/3-hour algorithm, 107 (66.8%) could be rule out with Roche hs-cTnT with no AMI missed (sensitivity 100% [95%CI: 90.5 to 100] and NPV 100%); 89 with Ortho hs-cTnI (sensitivity 97.3% [95%CI: 85.8-99.9] and NPV 98.8% [95%CI:92.7-99.8]); and 61 with Abbott hs-cTnI (sensitivity 97% [95%CI: 84.2-99.9] and NPV 98.4% [95%CI: 89.8-99.7]). For rule-in, 23.7% (n = 37) from the total population would be designated in this group, with a specificity of 86.9% (95%CI: 79.7-92.4) and PPV of 69.8% (95%CI: 59.4-78.5) vs specificity of 72.3% (95%CI:63.5-80.0) and PPV of 51.4% (95%CI: 44.1-58.2)with Roche hs-cTnT vs Ortho hs-cTnI respectively; and with Abbott, 33 patients had constitued this group with a specificity of 52.1% (95%CI:42.7-61.4) and PPV of 36.4% (95%CI: 32.0-41.0). In conclusion, according to ESC guidelines, our results indicate that the Ortho hs-cTnI assay for the Vitros 3600 instrument is a method that may be used in the clinical practice using 0/3-hour algorithm.

5 December 2023 in Bioanalysis
Verified
Journal Article
Closed access
BBBastien Baud
Bastien Baud
ADanne marie dupuy
anne marie dupuy
SZSamuel Zozor
Samuel Zozor
SBStéphanie Badiou
Stéphanie Badiou
ABAnne Sophie Bargnoux
Anne Sophie Bargnoux
JCJean Paul Cristol
Jean Paul Cristol
Background: The authors report the relevance of using a point of care test (Helge®) for free hemoglobin determination and concordance of the values the with Cobas® 8000 and spectrophotometer method...